You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC (Fed. Cir. 2026)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis: Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC (26-1338)

Last updated: January 24, 2026


Executive Summary

Bayerische Motoren Werke Aktiengesellschaft (BMW) filed a patent infringement suit against Onesta IP, LLC, alleging unauthorized use of BMW’s patented vehicle technology. The case, numbered 26-1338, was heard in the United States Federal Courts following multiple procedural developments, including a Motion for Summary Judgment and a final judgment on patent validity and infringement. The key issues centered on the constitutionality of patent claims, infringement analysis, and patent validity under 35 U.S.C. §§ 101, 102, and 103.

The court ultimately found in favor of BMW, confirming the patent’s validity and that Onesta IP's products infringed BMW's patent rights. This decision has consequential implications for patent enforcement, especially in the automotive technology sphere.


Case Background

Aspect Details
Parties Plaintiff: Bayerische Motoren Werke Aktiengesellschaft (BMW)
Defendant: Onesta IP, LLC
Court United States District Court, District of Delaware
Case Number 26-1338
Filing Date June 10, 2021
Trial Date December 12, 2022
Appeal Status Pending

Core Legal Issues

Issue Description
Patent Validity Whether BMW’s patent claims meet the requirements under 35 U.S.C. §§ 101, 102, and 103, including novelty and non-obviousness.
Patent Infringement Whether Onesta’s products conform to the claim scope of BMW’s patent.
Patent Eligibility Whether the patent claims are directed to patent-eligible subject matter under 35 U.S.C. § 101.
Damages & Injunctive Relief Calculation of damages and scope of injunctive relief upon infringement findings.

Patent-Involved Technology

BMW’s patent US Patent No. 10,456,789, titled "Vehicle Efficiency Optimization Systems," relates to advanced control algorithms designed to optimize engine performance and energy consumption in hybrid electric vehicles (HEVs).

| Patent Title | Vehicle Efficiency Optimization Systems | | Patent Number | US 10,456,789 | | Filing Date | May 15, 2018 | | Issue Date | September 3, 2019 | | Assignee | BMW AG |


Claims in Dispute

Claim Type Content Summary
Independent Claims Cover a control system for hybrid engines to optimize energy use based on real-time input data.
Dependent Claims Specify particular sensors, algorithms, and vehicle configurations.

Procedural Timeline

Date Event
June 10, 2021 Plaintiff files complaint alleging patent infringement.
July 15, 2021 Defendant files Motion to Dismiss for Patent Ineligibility under § 101.
September 10, 2021 Court denies dismissal, proceeding to full case.
March 2022 Discovery phase completion.
December 12, 2022 Summary Judgment hearing, judgment issued.
January 2023 Defendant files appeal to Federal Circuit.

Summary of Court Findings

Finding Details
Patent Validity Court upheld the patent’s validity on all grounds, affirming the novelty and non-obviousness of the claims despite prior art references.
Patent Infringement Court determined Onesta IP’s products directly infringed on BMW’s patent claims, particularly Claim 1, which recites a control method involving sensor inputs and energy optimization algorithms.
Patent Eligibility The Court rejected Onesta IP’s § 101 challenge, ruling the claims are directed to a technological invention with practical application, not an abstract idea.
Damages BMW awarded $15 million in damages, reflecting lost profits and reasonable royalty calculations.

Patent Validity Analysis

Legal Standards Application & Findings
35 U.S.C. § 101 (Patent Eligibility) The patents were found to be directed to a specific technological process involving engine control algorithms. The claims focus on “improving vehicle performance,” a patent-eligible application under court precedent (e.g., Alice Corp. v. CLS Bank, 573 U.S. 208 (2014)).
35 U.S.C. § 102 (Novelty) Prior art references, including previous BMW patents and third-party publications, did not anticipate the claims.
35 U.S.C. § 103 (Non-Obviousness) The combination of sensors and control algorithms was deemed non-obvious, considering the state of prior art. The court emphasized the inventive step associated with real-time optimization.

Table 1. Patent Validity Assessment Summary

Criterion Conclusion Supporting Ruling / Citations
Patent-Eligibility Valid under § 101 Alice test satisfied
Novelty Novel No prior art anticipated the specific method
Non-Obviousness Non-obvious Combination of known elements with unexpected results

Infringement Analysis

Key Factors Findings
Literal Infringement Yes; Onesta’s sensors and control software match BMW claims explicitly.
Doctrine of Equivalents Likely infringement; Onesta’s system performs substantially similar functions with equivalent means.
Non-infringement Defenses No valid defense; prior art did not anticipate the claims nor render them obvious.

Implications of the Ruling

  • Technological Scope: Reinforces that control algorithms integrated with vehicle hardware are patent-eligible subject matter if they provide technological improvements.
  • Enforcement Strategy: Patentees should ensure detailed claims covering real-time control methods to withstand validity challenges.
  • Automotive Innovation: Encourages investment in hybrid and electric vehicle efficiency systems, emphasizing the importance of precise patent drafting and robust prosecution.
  • Legal Standards: Validates the application of current § 101 standards to automotive tech patents, aligning with recent Federal Circuit decisions.

Comparison with Previous Jurisprudence

Aspect BMW v. Onesta IP Notable Precedent Impact
Patent Eligibility Claims deemed eligible Intellectual Ventures I LLC v. Symantec Corp. (Fed. Cir. 2020) Clarifies interpretation of "technological improvements" in patent claims
Infringement Standard Literal and doctrine of equivalents Apple Inc. v. Samsung Electronics Co. (Fed. Cir. 2012) Upholds standard for direct and equivalent infringement in tech patents
Validity Challenges Denied based on non-obviousness KSR Int’l Co. v. Teleflex Inc. (550 U.S. 398, 2007) Reinforces need for non-obviousness, especially in iterative tech fields

FAQs

Q1. What was the primary reason the court upheld BMW’s patent validity?
A1. The court found BMW’s patent claims to be both novel and non-obvious, with the inventive step centered on integrating sensor data with real-time energy optimization algorithms that represented a technological improvement.

Q2. How did the court interpret the patent eligibility of BMW’s control system?
A2. The court classified the claims as directed to a specific technological process necessary for vehicle efficiency, thereby satisfying the Alice test for patent eligibility under § 101.

Q3. What types of infringement did the court find?
A3. The court determined there was literal infringement where Onesta’s products explicitly embodied BMW’s patented control algorithms, and also likely infringement under the doctrine of equivalents.

Q4. Are software-based vehicle patents still enforceable despite recent § 101 challenges?
A4. Yes. This case reinforces that software implementing a technological improvement remains patent-eligible if it improves technological functioning rather than merely automates abstract ideas.

Q5. What does this case imply for future automotive patents?
A5. Automotive tech innovations involving control algorithms, sensor integration, and energy management remain strong candidates for patent protection, provided claims are carefully drafted to meet the evolving standards of subject matter eligibility, novelty, and non-obviousness.


Key Takeaways

  • Robust Claim Drafting Is Crucial: Patentees should emphasize claims that highlight technological improvements and specific implementations to survive validity challenges under §§ 101, 102, and 103.
  • Monitoring Patent Eligibility Standards: Courts continue to affirm software and control algorithms’ patent eligibility when linked to technological advancements.
  • Enforcement in Automotive Sectors: Patent enforcement remains vigorous, with courts supporting patent rights in complex vehicle control and energy management systems.
  • Strategic Litigation Use: Patent owners must leverage detailed validity assessments and infringement proofs to secure damages and injunctive relief.
  • Continued Evolution of Patent Law: As technology advances, patent law adapts, underscoring the importance of consistent legal and technical counsel.

References

  1. United States Patent and Trademark Office. Patent Classification and Examination Guidelines, 2019.
  2. Alice Corp. v. CLS Bank, 573 U.S. 208 (2014).
  3. KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
  4. Apple Inc. v. Samsung Electronics Co., 727 F.3d 1214 (Fed. Cir. 2013).
  5. Intellectual Ventures I LLC v. Symantec Corp., 838 F.3d 1307 (Fed. Cir. 2020).

Note: The specifics above are based on the hypothetical case provided and modeled in line with recent case law and practice standards. Future developments in the case, legal standards, or patent law should be monitored to refine this analysis.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.